US 12,454,579 B2
Compositions and methods for inhibiting T cell exhaustion
Crystal Mackall, Stanford, CA (US); Rachel Lynn, Redwood City, CA (US); Evan Weber, Redwood City, CA (US); and Elena Sotillo, Redwood City, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Jun. 27, 2022, as Appl. No. 17/850,825.
Application 17/850,825 is a division of application No. 16/221,155, filed on Dec. 14, 2018, granted, now 11,400,117.
Claims priority of provisional application 62/738,687, filed on Sep. 28, 2018.
Claims priority of provisional application 62/599,299, filed on Dec. 15, 2017.
Prior Publication US 2022/0401486 A1, Dec. 22, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 38/17 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/3084 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4205 (2025.01); A61K 40/4211 (2025.01); A61K 40/4212 (2025.01); A61K 40/4258 (2025.01); A61P 35/00 (2018.01); C07K 14/4702 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C07K 16/32 (2013.01); A61K 38/1709 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05); A61K 2239/48 (2023.05); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)] 10 Claims
 
1. A composition comprising isolated T cells,
wherein the T cells are engineered to express a human c-Jun and an engineered receptor specific for a tumor antigen,
wherein the human c-Jun and the engineered receptor are expressed from separate expression vectors or co-expressed from a single expression vector as separate polypeptides,
wherein the engineered receptor is a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), and
wherein the T cells exhibit a Th1 cytokine profile.